Modification of <ce:italic>Mecp2</ce:italic> dosage alters axonal transport through the Huntingtin/Hap1 pathway

@article{Roux2012ModificationO,
  title={Modification of <ce:italic>Mecp2</ce:italic> dosage alters axonal transport through the Huntingtin/Hap1 pathway},
  author={Jean-Christophe Roux and Diana Zala and Nicolas Panayotis and Ana Borges-Correia and Laurent Villard},
  journal={Neurobiology of Disease},
  year={2012},
  volume={45},
  pages={786-795}
}
Mecp2 deficiency or overexpression causes a wide spectrum of neurological diseases in humans among which Rett Syndrome is the prototype. Pathogenic mechanisms are thought to involve transcriptional deregulation of target genes such as Bdnf together with defects in the general transcriptional program of affected cells. Here we found that two master genes, Huntingtin (Htt) and huntingtin-associated protein (Hap1), involved in the control of Bdnf axonal transport, are altered in the brain of Mecp2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

MeCP2: a novel Huntingtin interactor.

Human molecular genetics • 2014
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…